Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs...

Prof Nadia Harbeck - University of Munich, Munich, Germany

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC ( Prof Nadia Harbeck - University of Munich, Munich, Germany )

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally...

Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )

B-cell maturation antigen targeted CD3-engaging bispecific molecule for...

Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville...

$B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )$

MRD-guided therapy debate

Prof Ola Landgren - University of Miami, Miami, USA

MRD-guided therapy debate ( Prof Ola Landgren - University of Miami, Miami, USA )

KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in...

Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA

KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma ( Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA )

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical...

Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer ( Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA )

OncoAlert and ecancer - ESMO 2021 Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast...

Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer ( Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom )

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or...

Prof Thomas Powles - Queen Mary University of London, London, UK

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )

ESMO President: What to watch for at ESMO 2021

Prof Solange Peters - ESMO President

ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant...

Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma ( Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland )

More from ecancer